Efficacy of Hedgehog inhibitors in acute myeloid leukemia and establishment of valid biomarkers

[Rinshō ketsueki] The Japanese journal of clinical hematology
Yosuke Minami

Abstract

Hedgehog (Hh) signaling pathway plays an important role in embryonic patterning and organ development. Its aberrant activation is involved in many types of cancers and is required for the maintenance of patients with leukemic stem cell (LSC). Clinical phase trials of SMO (a positive regulator in the Hh signaling pathway) inhibitors are currently underway in hematologic malignancies, such as acute myeloid leukemia (AML).

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.